Actavis Said to Have Spurned $15 Billion Offer

May 14 (Bloomberg) -- Actavis rejected a cash-and-stock offer from fellow generic drugmaker Mylan for $15 billion, deciding instead to pursue talks to take over Warner Chilcott, said people familiar with the matter. (Source: Bloomberg)
Tesla's Marketing Strategy Is Brilliant: Patterson
59:06 - May 1 -- MatlinPatterson Global Advisers' Mark Patterson discusses Tesla branching out into the battery business with Bloomberg's Alix Steel on "Street Smart."
  • What’s Delaying the Arrival of Apple Watches?
  • Greece Is Going to Go Bankrupt: Patterson
  • How to Short Negative-Yielding Debt